Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips has appointed Shez Partovi as Chief Innovation & Strategy Officer, effective March 22, 2021, succeeding Jeroen Tas. Partovi, previously with Amazon Web Services, brings extensive experience in healthcare and technology. Tas will transition to a part-time role until the end of 2022, focusing on strategic business development. Additionally, Rob Cascella will retire from the Executive Committee on April 1, 2021, while continuing as a special advisor. Philips aims to enhance its solutions leadership through deep clinical insights and big data analytics.
Summary not available.
Summary not available.
Summary not available.
Royal Philips (NYSE: PHG) announced significant changes to its Supervisory Board as part of its ongoing governance evolution. Effective upon the conclusion of the 2021 Annual General Meeting of Shareholders on May 6, 2021, Chairman Jeroen van der Veer and Vice-Chairwoman Christine Poon will retire after their third terms. Feike Sijbesma is appointed as the new Chairman, with Paul Stoffels as Vice-Chairman. New board members proposed include Chua Sock Koong and Indra Nooyi, both bringing extensive leadership experience in technology and sustainability, which aligns with Philips’ health technology focus.
Summary not available.
Summary not available.
Philips (NYSE: PHG) has successfully completed the acquisition of BioTelemetry (NASDAQ: BEAT), creating a global leader in patient care management solutions for hospitals and homes. The acquisition consolidates BioTelemetry's $450 million sales and its extensive remote cardiac monitoring services into Philips’ Connected Care business segment. The deal is expected to yield nominal sales growth and positive EBITA margins in 2021, with ambitions for double-digit growth and over 20% EBITA margin by 2025.
Royal Philips has completed its tender offer to acquire all outstanding shares of BioTelemetry for USD 72.00 per share in cash. The Offer, which expired on February 9, 2021, resulted in 27,182,062 shares being tendered, representing approximately 78.96% of BioTelemetry's outstanding shares. Following the merger, BioTelemetry will become a wholly owned subsidiary of Philips, with shares converting into cash payments, and will be delisted from NASDAQ.
Royal Philips (NYSE: PHG) has formed a 5-year strategic partnership with the Dutch SAZ group, comprising 28 hospitals, to advance connected care. This collaboration focuses on enhancing patient monitoring and self-management, incorporating Philips' technologies.
The initiative aims to shift care closer to patients' homes, reduce ICU readmissions, and improve health outcomes through early detection. Notably, projects in 2021 will include in-hospital applications and home monitoring for chronic conditions, leveraging the Engage platform for patient data management.